mybacs Revenue and Competitors

Zug,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • mybacs's estimated annual revenue is currently $5.9M per year.(i)
  • mybacs's estimated revenue per employee is $155,000

Employee Data

  • mybacs has 38 Employees.(i)
  • mybacs grew their employee count by 46% last year.

mybacs's People

NameTitleEmail/Phone
1
Founder & CEOReveal Email/Phone
2
Head Performance MarketingReveal Email/Phone
3
Country managerReveal Email/Phone
4
Senior Operations ManagerReveal Email/Phone
5
Business Development ManagerReveal Email/Phone
6
Online Marketing Managerin | Loyalty & RetentionReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is mybacs?

mybacs is a DTC, research-driven, Biotechnology company specialized in the human microbiome. Our goal is to revolutionize the market around intestinal healthcare and thus make a decisive contribution to the daily well-being of our customers. Our team of pharmaceutical scientists and physicians is focused on the development of innovative and highly-dosed synbiotic supplements. These are aligned by our singular formulations from specifically selected probiotic cultures, prebiotics as well as minerals and vitamins tailored to the individual needs of our customers.

keywords:N/A

N/A

Total Funding

38

Number of Employees

$5.9M

Revenue (est)

46%

Employee Growth %

N/A

Valuation

N/A

Accelerator

mybacs News

2022-03-30 - Human Microbiome-based Gut Health Test and Nutrition Market ...

The important key players are Seed Health, ResBiotic, Fitbiomics, HSK Genetech, Mybacs, Affinity DNA, Freshly fermented, Carbiotix, Troo,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4M386%N/A
#2
$4M389%N/A
#3
$6.2M40-69%N/A
#4
$7M40-13%N/A
#5
$7.2M4132%N/A